VESPER-1: the durability signal In a 32-week exploratory extension (Part B) of VESPER-1, Pfizer reports a 15.9% non-placebo-adjusted weight loss with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide in participants who escalated from placebo to active drug
Across organ systems, this will require incorporation of validated imaging modalities and circulating or tissue-based biomarkers of fibrogenesis and matrix turnover
Before that, however, it must survive being degraded in the gut by enzyme -glutamyl transpeptidase (GGT)
Full-text articles of potentially eligible studies were retrieved for detailed evaluation
Why Weight Regain Happens After Stopping GLP-1s GLP-1 medications work by mimicking a hormone that helps regulate appetite, blood sugar, and digestion
Having controlled glucose levels can help prevent severe complications from type 2 diabetes like kidney disease, retinal diseases, neuropathy (losing feeling in the hands and feet), and development of non-healing wounds in the feet, and experts are now looking into whether GLP-1s reduce the risk for those complications